trending Market Intelligence /marketintelligence/en/news-insights/trending/6yKK0lvFgMjIO5mpg_kovg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

BioTime forms unit to develop human aging programs

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


BioTime forms unit to develop human aging programs

BioTime Inc. formed a new unit, AgeX Therapeutics Inc., to consolidate certain subsidiaries and programs in the field of interventional gerontology.

AgeX will be focused on applying technology related to pluripotent stem cells and telomere biology to aging and age-related disease.

The formation enables BioTime to simplify its corporate structure and operations and focus its resources on the clinical development of its two lead programs, Renevia and OpRegen.

AgeX's formation also provides the new unit greater flexibility for financing alternatives, BioTime said in a news release.